Impel Neuropharma Stock Net Income
Fundamental analysis of Impel Neuropharma allows traders to better anticipate movements in Impel Neuropharma's stock price by examining its financial health and performance throughout various phases of its business cycle.
Impel |
Impel Neuropharma Company Net Income Analysis
Impel Neuropharma's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Impel Neuropharma Net Income | (74.28 M) |
Most of Impel Neuropharma's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Impel Neuropharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Impel Neuropharma reported net income of (74.28 Million). This is 121.76% lower than that of the Biotechnology sector and 206.04% lower than that of the Health Care industry. The net income for all United States stocks is 113.01% higher than that of the company.
Impel Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Impel Neuropharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Impel Neuropharma could also be used in its relative valuation, which is a method of valuing Impel Neuropharma by comparing valuation metrics of similar companies.Impel Neuropharma is currently under evaluation in net income category among its peers.
Impel Fundamentals
| Return On Equity | -25.46 | |||
| Return On Asset | -0.62 | |||
| Operating Margin | (2.55) % | |||
| Current Valuation | 115.52 M | |||
| Shares Outstanding | 23.9 M | |||
| Shares Owned By Insiders | 0.52 % | |||
| Shares Owned By Institutions | 71.61 % | |||
| Number Of Shares Shorted | 851.5 K | |||
| Price To Book | 18.46 X | |||
| Price To Sales | 0.05 X | |||
| Revenue | 20.99 M | |||
| Gross Profit | 6.16 M | |||
| EBITDA | (68.96 M) | |||
| Net Income | (74.28 M) | |||
| Cash And Equivalents | 97.83 M | |||
| Cash Per Share | 4.12 X | |||
| Total Debt | 51.19 M | |||
| Current Ratio | 6.26 X | |||
| Book Value Per Share | (3.87) X | |||
| Cash Flow From Operations | (79.09 M) | |||
| Short Ratio | 0.36 X | |||
| Earnings Per Share | (3.12) X | |||
| Target Price | 40.0 | |||
| Number Of Employees | 160 | |||
| Beta | 1.17 | |||
| Market Capitalization | 5.76 M | |||
| Total Asset | 88.55 M | |||
| Retained Earnings | (321.11 M) | |||
| Working Capital | 57.65 M | |||
| Z Score | -6.56 | |||
| Net Asset | 88.55 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Impel Stock
If you are still planning to invest in Impel Neuropharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Impel Neuropharma's history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |